Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

被引：22

作者：

Gay, Francesca ^{[1
]}

Cerrato, Chiara ^{[1
]}

Scalabrini, Delia Rota ^{[1
]}

Galli, Monica ^{[1
]}

Belotti, Angelo ^{[1
]}

Zamagni, Elena ^{[1
]}

Ledda, Antonio ^{[1
]}

Grasso, Mariella ^{[1
]}

Angelucci, Emanuele ^{[1
]}

Liberati, Anna Marina ^{[1
]}

Tosi, Patrizia ^{[1
]}

Pisani, Francesco ^{[1
]}

Spada, Stefano ^{[1
]}

Annibali, Ombretta ^{[1
]}

Baraldi, Anna ^{[1
]}

Omede, Paola ^{[1
]}

Galieni, Piero ^{[1
]}

Rizzi, Rita ^{[1
]}

Pescosta, Norbert ^{[1
]}

Ronconi, Sonia ^{[1
]}

Vincelli, Donatella ^{[1
]}

Cafro, Anna Maria ^{[1
]}

Offidani, Massimo ^{[1
]}

Palumbo, Antonio ^{[2
,3
]}

Musto, Pellegrino ^{[1
]}

Cavo, Michele ^{[1
]}

Boccadoro, Mario ^{[1
]}

机构：

[1] European Myeloma Network, GIMEMA, Milan, Italy

[2] Univ Torino, Turin, Italy

[3] Takeda Pharmaceut Co, Zurich, Switzerland

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-112093

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

121

引用

页数：4

共 50 条

[41] Carfilzomib-lenalidomide-dexamethasone Vs. lenalidomide-dexamethasone in non-frail transplant-ineligible patients with newly diagnosed multiple myeloma: the EMN20 trial
D'Agostino, Mattia
Antonioli, Elisabetta
Gamberi, Barbara
Bruno, Benedetto
Derudas, Daniele
Tosi, Patrizia
Fazio, Francesca
Carlo-Stella, Carmelo
Ronconi, Sonia
Corradini, Paolo
Ballanti, Stelvio
Cellini, Claudia
Falcone, Antonietta Pia
Bringhen, Sara
Offidani, Massimo
Rambaldi, Alessandro
Rota-Scalabrini, Delia
Agazzi, Alberto
Casaluci, Gloria Margiotta
Pietrantuono, Giuseppe
Patriarca, Francesca
Larocca, Alessandra
Boccadoro, Mario
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S94 - S95
[42] Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)
Bringhen, Sara
Antonioli, Elisabetta
Gamberi, Barbara
Bruno, Benedetto
Derudas, Daniele
Tosi, Patrizia
Fazio, Francesca
Mazza, Rita
Ronconi, Sonia
Corradini, Paolo
Lotti, Flavia
Cellini, Claudia
Falcone, Antonietta Pia
Galieni, Piero
Ria, Roberto
Belotti, Angelo
Mannina, Donato
Cafro, Anna Maria
Cangialosi, Clotilde
Vincelli, Iolanda Donatella
Lombardo, Alessandra
Larocca, Alessandra
Boccadoro, Mario
D'Agostino, Mattia
BLOOD, 2023, 142
[43] Planned Interim Analysis of the GMMG-CONCEPT Trial investigating Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma
Leypoldt, L.
Besemer, B.
Haenel, M.
Raab, M. -S
Mann, C.
Munder, M.
Reinhardt, H. C.
Nogai, A.
Goerner, M.
Ko, Y. -D
de Wit, M.
Salwender, H.
Scheid, C.
Graeven, U.
Peceny, R.
Staib, P.
Dieing, A.
Einsele, H.
Jauch, A.
Zago, M.
Benner, A.
Tichy, D.
Bokemeyer, C.
Goldschmidt, H.
Weisel, K.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 55 - 56
[44] Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).
Zimmerman, Todd M.
Griffith, Kent A.
Jasielec, Jagoda
Rosenbaum, Cara Ann
McDonnell, Kathryn
Waite-Marin, Jessica
Berdeja, Jesus G.
Raje, Noopur S.
Reece, Donna Ellen
Vij, Ravi
Alonge, Mattina
Rosebeck, Shaun
Gurbuxani, Sandeep
Faham, Malek
Kong, Katherine A.
Levy, Joan
Jakubowiak, Andrzej J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[45] Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooij, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique C.
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk M.
Broyl, Annemiek
Iskander, Karim Saad
Sonneveld, Pieter
BLOOD, 2017, 130
[46] GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years
Mateos, Maria-Victoria
Paiva, Bruno
Cedena Romero, Maria Teresa
Puig, Noemi
Sureda Balari, Anna Maria
Oriol, Albert
Ocio, Enrique M.
Rosinol, Laura
Gonzalez-Montes, Yolanda
Jose Bargay, Juan
Gonzalez Garcia, Esther
Hernandez Garcia, Miguel Teodoro
Ramirez, Angel
Suarez-Cabrera, Alexia
Blanchard, Maria-Jesus
Garzon, Sebastian
Casado Montero, Luis Felipe
Cabanas Perianes, Valentin
Perez De Oteyza, Jaime
Gironella, Mercedes
Martinez-Lopez, Joaquin
Ana-Isabel-Teruel
Delgado, Pilar
Prieto, Elena
Lahuerta Palacios, Juan Jose
Blade, Joan
San Miguel, Jesus
BLOOD, 2023, 142
[47] Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial
Costa, Luciano J.
Chhabra, Saurabh
Medvedova, Eva
Schmidt, Timothy Martin
Dholaria, Bhagirathbhai
Godby, Kelly N.
Silbermann, Rebecca
Bal, Susan
D'Souza, Anita
Giri, Smith
Omel, James L.
Hari, Parameswaran
Callander, Natalie
Dhakal, Binod
BLOOD, 2022, 140 : 7275 - 7277
[48] Depth of response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in front-line induction of high-risk Multiple Myeloma: Interim analysis of the GMMG-CONCEPT trial
Weisel, K. C.
Asemissen, A. M.
Leypoldt, L.
Besemer, B.
Haenel, M.
Blau, I. W.
Goerner, M.
Ko, Y. -D.
Duerig, J.
Staib, P.
Mann, C.
Lutz, R.
Munder, M.
Graeven, U.
Peceny, R.
Salwender, H.
Zago, M.
Benner, A.
Tichy, D.
Bokemeyer, C.
Goldschmidt, H.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 91 - 92
[49] Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
van Duin, Mark
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooy, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk M.
Broijl, Annemiek
Sonneveld, Pieter
BLOOD, 2016, 128 (22)
[50] Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooy, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk
Broijl, Annemiek
Sonneveld, Pieter
HAEMATOLOGICA, 2019, 104 (11) : 2265 - 2273

← 1 2 3 4 5 →